Advertisement
Screener

IRONWOOD PHARMACEUTICALS, INC. (IRWD) Net Income (Loss) Available to Common Stockholders, Basic

2.8 / 5 stars · 68/120 Roast Me

IRONWOOD PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic

IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Net Income (Loss) Available to Common Stockholders, Basic of $51.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06

  • IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $51.29M, a 117.34% increase year-over-year.
  • IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $40.77M.
  • IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$2.28M, a 200.89% decline year-over-year.
  • IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $40.08M, a 999.29% increase year-over-year.
  • IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was $24.02M, a 2629.20% increase from fiscal 2024.
  • IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was $880.00K.
  • IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$1.00B, a 672.50% decline from fiscal 2022.
  • IRONWOOD PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was $175.06M, a 66.87% decline from fiscal 2021.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 6 monthNet Income (Loss) Available to Common Stockholders, Basic 9 monthNet Income (Loss) Available to Common Stockholders, Basic 12 month
2026-06-30$51.29M
10-Q · filed 2026-08-06
$92.06M
10-Q · filed 2026-08-06
$89.79M
derived: sum of 3 quarters · filed 2026-08-06
$129.87M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$40.77M
10-Q · filed 2026-05-07
$38.50M
derived: sum of 2 quarters · filed 2026-05-07
$78.58M
derived: sum of 3 quarters · filed 2026-05-07
$102.18M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$2.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$37.80M
derived: sum of 2 quarters · filed 2026-02-26
$61.40M
derived: sum of 3 quarters · filed 2026-08-06
$24.02M
10-K · filed 2026-02-26
2025-09-30$40.08M
10-Q · filed 2025-11-10
$63.68M
derived: sum of 2 quarters · filed 2026-08-06
$26.29M
10-Q · filed 2025-11-10
$28.55M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$23.60M
10-Q · filed 2026-08-06
-$13.79M
10-Q · filed 2026-08-06
-$11.53M
derived: sum of 3 quarters · filed 2026-08-06
-$7.88M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$37.39M
10-Q · filed 2026-05-07
-$35.13M
derived: sum of 2 quarters · filed 2026-05-07
-$31.48M
derived: sum of 3 quarters · filed 2026-05-07
-$32.34M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$2.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$5.90M
derived: sum of 2 quarters · filed 2026-02-26
$5.04M
derived: sum of 3 quarters · filed 2026-02-26
$880.00K
10-K · filed 2026-02-26
2024-09-30$3.65M
10-Q · filed 2025-11-10
$2.79M
derived: sum of 2 quarters · filed 2025-11-10
-$1.38M
10-Q · filed 2025-11-10
-$2.46M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30-$860.00K
10-Q · filed 2025-08-11
-$5.02M
10-Q · filed 2025-08-11
-$6.11M
derived: sum of 3 quarters · filed 2025-08-11
$9.21M
derived: sum of 4 quarters · filed 2025-08-11
2024-03-31-$4.16M
10-Q · filed 2024-05-09
-$5.25M
derived: sum of 2 quarters · filed 2025-03-31
$10.07M
derived: sum of 3 quarters · filed 2025-03-31
2023-12-31-$1.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$14.23M
derived: sum of 2 quarters · filed 2025-03-31
-$1.00B
10-K · filed 2025-03-31
2023-09-30$15.32M
10-Q · filed 2024-11-07
-$1.00B
10-Q · filed 2024-11-07
2023-03-31$45.71M
10-Q · filed 2024-05-09
$94.58M
derived: sum of 2 quarters · filed 2025-03-31
$144.90M
derived: sum of 3 quarters · filed 2025-03-31
$181.98M
derived: sum of 4 quarters · filed 2025-03-31
2022-12-31$48.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$99.18M
derived: sum of 2 quarters · filed 2025-03-31
$136.26M
derived: sum of 3 quarters · filed 2025-03-31
$175.06M
10-K · filed 2025-03-31
2022-09-30$50.32M
10-Q · filed 2023-11-09
$87.40M
derived: sum of 2 quarters · filed 2023-11-09
$126.20M
10-Q · filed 2023-11-09
$167.57M
derived: sum of 4 quarters · filed 2024-02-16
2022-06-30$37.08M
10-Q · filed 2022-08-04
$75.88M
10-Q · filed 2022-08-04
$117.25M
derived: sum of 3 quarters · filed 2024-02-16
$173.10M
derived: sum of 4 quarters · filed 2024-02-16
2022-03-31$38.80M
10-Q · filed 2023-05-04
$80.17M
derived: sum of 2 quarters · filed 2024-02-16
$136.02M
derived: sum of 3 quarters · filed 2024-02-16
$527.32M
derived: sum of 4 quarters · filed 2024-02-16
2021-12-31$41.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16
$97.22M
derived: sum of 2 quarters · filed 2024-02-16
$488.52M
derived: sum of 3 quarters · filed 2024-02-16
$528.45M
10-K · filed 2024-02-16
2021-09-30$55.84M
10-Q · filed 2022-11-03
$447.15M
derived: sum of 2 quarters · filed 2022-11-03
$487.07M
10-Q · filed 2022-11-03
$530.28M
derived: sum of 4 quarters · filed 2023-02-16
2021-06-30$391.30M
10-Q · filed 2022-08-04
$431.23M
10-Q · filed 2022-08-04
$474.43M
derived: sum of 3 quarters · filed 2023-02-16
$508.86M
derived: sum of 4 quarters · filed 2023-02-16
2021-03-31$39.93M
10-Q · filed 2022-05-05
$83.13M
derived: sum of 2 quarters · filed 2023-02-16
$117.55M
derived: sum of 3 quarters · filed 2023-02-16
$142.76M
derived: sum of 4 quarters · filed 2023-02-16
2020-12-31$43.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16
$77.63M
derived: sum of 2 quarters · filed 2023-02-16
$102.83M
derived: sum of 3 quarters · filed 2023-02-16
$106.18M
10-K · filed 2023-02-16
2020-09-30$34.42M
10-Q · filed 2021-11-04
$59.63M
derived: sum of 2 quarters · filed 2021-11-04
$62.97M
10-Q · filed 2021-11-04
2020-06-30$25.20M
10-Q · filed 2021-08-05
$28.55M
10-Q · filed 2021-08-05
2020-03-31$3.35M
10-Q · filed 2021-05-06
2019-12-31$21.50M
10-K · filed 2022-02-18
2018-12-31-$282.37M
10-K · filed 2021-02-17
2017-03-31-$52.50M
10-Q · filed 2017-05-08
-$66.01M
derived: sum of 2 quarters · filed 2017-05-08
-$99.21M
derived: sum of 3 quarters · filed 2017-05-08
-$120.91M
derived: sum of 4 quarters · filed 2017-05-08
2016-12-31-$13.51M
10-K · filed 2017-02-22
-$46.71M
derived: sum of 2 quarters · filed 2017-02-22
-$68.41M
derived: sum of 3 quarters · filed 2017-02-22
-$81.71M
10-K · filed 2017-02-22
2016-09-30-$33.20M
10-K · filed 2017-02-22
-$54.91M
derived: sum of 2 quarters · filed 2017-02-22
-$68.20M
10-Q · filed 2016-11-07
-$82.24M
derived: sum of 4 quarters · filed 2017-05-08
2016-06-30-$21.70M
10-K · filed 2017-02-22
-$35.00M
10-Q · filed 2016-08-08
-$49.04M
derived: sum of 3 quarters · filed 2017-05-08
-$96.43M
derived: sum of 4 quarters · filed 2017-05-08
2016-03-31-$13.30M
10-Q · filed 2017-05-08
-$27.33M
derived: sum of 2 quarters · filed 2017-05-08
-$74.72M
derived: sum of 3 quarters · filed 2017-05-08
-$122.74M
derived: sum of 4 quarters · filed 2017-05-08
2015-12-31-$14.04M
10-K · filed 2017-02-22
-$61.43M
derived: sum of 2 quarters · filed 2017-02-22
-$109.45M
derived: sum of 3 quarters · filed 2017-02-22
-$142.67M
10-K · filed 2017-02-22
2015-09-30-$47.39M
10-K · filed 2017-02-22
-$95.41M
derived: sum of 2 quarters · filed 2017-02-22
-$128.63M
10-Q · filed 2016-11-07
-$166.28M
derived: sum of 4 quarters · filed 2017-02-22
2015-06-30-$48.02M
10-K · filed 2017-02-22
-$81.24M
10-Q · filed 2016-08-08
-$118.89M
derived: sum of 3 quarters · filed 2017-02-22
-$160.88M
derived: sum of 4 quarters · filed 2017-02-22
2015-03-31-$33.22M
10-K · filed 2017-02-22
-$70.87M
derived: sum of 2 quarters · filed 2017-02-22
-$112.86M
derived: sum of 3 quarters · filed 2017-02-22
-$173.21M
derived: sum of 4 quarters · filed 2017-02-22
2014-12-31-$37.65M
10-K · filed 2016-02-19
-$79.64M
derived: sum of 2 quarters · filed 2016-02-19
-$139.99M
derived: sum of 3 quarters · filed 2016-02-19
-$189.62M
10-K · filed 2017-02-22
2014-09-30-$41.99M
10-K · filed 2016-02-19
-$102.34M
derived: sum of 2 quarters · filed 2016-02-19
-$151.97M
10-Q · filed 2015-11-05
-$203.96M
derived: sum of 4 quarters · filed 2016-02-19
2014-06-30-$60.36M
10-K · filed 2016-02-19
-$109.98M
10-Q · filed 2015-08-07
-$161.97M
derived: sum of 3 quarters · filed 2016-02-19
-$223.74M
derived: sum of 4 quarters · filed 2016-02-19
2014-03-31-$49.63M
10-K · filed 2016-02-19
-$101.61M
derived: sum of 2 quarters · filed 2016-02-19
-$163.39M
derived: sum of 3 quarters · filed 2016-02-19
-$228.54M
derived: sum of 4 quarters · filed 2016-02-19
2013-12-31-$51.99M
10-K · filed 2015-02-18
-$113.76M
derived: sum of 2 quarters · filed 2015-02-18
-$178.91M
derived: sum of 3 quarters · filed 2015-02-18
-$272.81M
10-K · filed 2016-02-19
2013-09-30-$61.77M
10-K · filed 2015-02-18
-$126.92M
derived: sum of 2 quarters · filed 2015-02-18
-$220.83M
10-Q · filed 2014-11-05
-$264.68M
derived: sum of 4 quarters · filed 2015-02-18
2013-06-30-$65.15M
10-K · filed 2015-02-18
-$159.05M
10-Q · filed 2014-08-05
-$202.91M
derived: sum of 3 quarters · filed 2015-02-18
-$155.27M
derived: sum of 4 quarters · filed 2015-02-18
2013-03-31-$93.90M
10-K · filed 2015-02-18
-$137.76M
derived: sum of 2 quarters · filed 2015-02-18
-$90.12M
derived: sum of 3 quarters · filed 2015-02-18
-$130.93M
derived: sum of 4 quarters · filed 2015-02-18
2012-12-31-$43.85M
10-K · filed 2014-02-07
$3.78M
derived: sum of 2 quarters · filed 2014-02-07
-$37.02M
derived: sum of 3 quarters · filed 2014-02-07
-$72.62M
10-K · filed 2015-02-18
2012-09-30$47.63M
10-K · filed 2014-02-07
$6.83M
derived: sum of 2 quarters · filed 2014-02-07
-$28.77M
10-Q · filed 2013-10-28
-$35.74M
derived: sum of 4 quarters · filed 2014-02-07
2012-06-30-$40.80M
10-K · filed 2014-02-07
-$76.40M
10-Q · filed 2013-08-08
-$83.38M
derived: sum of 3 quarters · filed 2014-02-07
-$104.01M
derived: sum of 4 quarters · filed 2014-02-07
2012-03-31-$35.60M
10-K · filed 2014-02-07
-$42.58M
derived: sum of 2 quarters · filed 2014-02-07
-$63.21M
derived: sum of 3 quarters · filed 2014-02-07
-$82.05M
derived: sum of 4 quarters · filed 2014-02-07
2011-12-31-$6.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-07
-$27.61M
derived: sum of 2 quarters · filed 2014-02-07
-$46.45M
derived: sum of 3 quarters · filed 2014-02-07
-$64.85M
10-K · filed 2014-02-07
2011-09-30-$20.63M
10-Q · filed 2012-11-06
-$39.48M
derived: sum of 2 quarters · filed 2012-11-06
-$57.88M
10-Q · filed 2012-11-06
-$69.53M
derived: sum of 4 quarters · filed 2012-11-06
2011-06-30-$18.84M
10-Q · filed 2012-08-07
-$37.24M
10-Q · filed 2012-08-07
-$48.90M
derived: sum of 3 quarters · filed 2012-08-07
-$57.17M
derived: sum of 4 quarters · filed 2012-08-07
2011-03-31-$18.40M
10-Q · filed 2012-05-10
-$30.05M
derived: sum of 2 quarters · filed 2012-05-10
-$38.32M
derived: sum of 3 quarters · filed 2012-05-10
-$55.46M
derived: sum of 4 quarters · filed 2012-05-10
2010-12-31-$11.65M
10-K · filed 2012-02-29
-$19.92M
derived: sum of 2 quarters · filed 2012-02-29
-$37.06M
derived: sum of 3 quarters · filed 2012-02-29
-$52.98M
10-K · filed 2013-02-21
2010-09-30-$8.27M
10-K · filed 2012-02-29
-$25.41M
derived: sum of 2 quarters · filed 2012-02-29
-$41.33M
10-Q · filed 2011-11-09
2010-06-30-$17.14M
10-K · filed 2012-02-29
-$33.06M
derived: sum of 2 quarters · filed 2012-02-29
2010-03-31-$15.92M
10-K · filed 2012-02-29
2009-12-31-$71.19M
10-K · filed 2012-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
Verastem, Inc. (VSTM)United States$0.706B-1.71
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Faeth Therapeutics, Inc. (FTH)United States$0.750B
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Neurogene Inc. (NGNE)$0.625B-4.46
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78